New designs for cancer vaccine and artificial veto cells: An emerging palette of protein paints

Immunologic Research

Volumn 27, Issue 2-3, 2003, Pages 565-574

  Tykocinski, Mark L ^a   Chen, Aoshuang ^a   Huang, Jui Han ^a   Weber, Matthew C ^a   Zheng, Guoxing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antigen presenting cell; Cancer vaccine; Costimulator blockade; Immunoregulation; Protein transfer; Veto cell

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; INTERLEUKIN 12; INTERLEUKIN 2;

ANTIGEN PRESENTING CELL; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; PROTEIN ENGINEERING; T-LYMPHOCYTES;

EID: 0042020012     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:2-3:565     Document Type: Review

References (78)

1. Knight SC, Stagg AJ: Antigen-presenting cell types. Curr Opin Immunol 1993;5:374-382.
2. Tykocinski ML, Kaplan DR, Medof ME: Antigen-presenting cell engineering. The molecular toolbox. Amer J Pathol 1996;148:1-16.
3. Chambers CA, Allison JP: Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999;11:203-210.
4. Coyle AJ, Gutierrez-Ramos J-C: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nature Immunol 2001;2:203-209.
5. Medof ME, Lublin DM, Holers VM, et al.: Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA 1987;84:2007-2011.
6. Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW, Nussenzweig V: Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987;325:545-549.
7. Tykocinski ML, Shu HK, Ayers DJ, et al.: Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci USA 1988;85:3555-3559.
8. Caras IW, Weddell GN, Davitz MA, Nussenzweig V, Martin JDW: Signal for attachment of a phopholipid membrane anchor in decay accelerating factor, Science. 1987;238:1280-1283.
9. Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984;160:1558-1578.
10. Huang J-H, Greenspan NS, Tykocinski ML: Alloantigenic recognition of artificial glycosylphosphatidylinositol-anchored HLA-A2.1. Mol Immunol. 1994;31:1017-1028.
11. Huang JH, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML: Protein transfer of preformed MHC-peptide complexes sensitizestarget cells to T cell cytolysis. Immunity 1994;1:607-613.
12. Geho DH, Fayen JD, Jackman RM, Moody BD, Porcelli SA, Tykocinski ML: Glycosyl-phosphastidylinositol reanchoring unmasks distinct antigen-presenting pathways for CD1b and CD1c. J. Immunol. 2000;65:1272-1277.
13. Weber MC, Groger RK, Tykocinski ML: A glycosylphosphatidylinositol-anchored cytokine can function as an artificial cellular adhesin. Exp Cell Res 1994;145:1646-1652.
14. Lin AY, Devaux B, Green A, Sogerstrom C, Elliot JF, Davis MM: Expression of T-cell antigen receptor heterodimers in a lipid-linked form. Science 1990;249:677-679.
15. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML: Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function, J Immunol. 1995;155:5498-5505.
16. Brunschwig EB, Fayen JD, Medof ME, Tykocinski ML: Protein transfer of glycosylphosphatidylinositol (GPI)-modified murine BT-1 and B7-2 costimulators. J Immunother 1999;22:390-400.
17. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P: Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995;92:8059-8063.
18. McHugh RS, Nagarajan S, Wang Y-C, Sell KW, Selvaraj P: Protein transfer of glycosylphosphatidylinositol-B7-1 into tumor cell membranes: A novel approach to tumor immunotherapy. Cancer Res 1999;59:2433-2437.
19. Chen A, Zheng G, Tykocinski ML: Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. J Immunol 2000;164:705-711.
20. Kim SA, Peacock JS: The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions. J Immunol Meth. 1993;158:57-65.
21. Viola A, Lanzavecchia A: T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104-106.
22. Itoh Y, Germain RN: Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells. J. Exp. Med. 1997;186:757-766.
23. Rachmilewitz J, Riely GJ, Huang J-H, Chen A, Tykocinski ML: A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds. Blood 2001;98:3727-3732.
24. Tykocinski ML, Kaplan DR, Medof ME: Antigen-presenting cell engineering. The molecular toolbox. Am J Pathol 1996;148:1-16.
25. Tykocinski ML: Engineering cellular cancer vaccines: gene and protein transfer options; in: Gerson S, Lattime E (eds.): Gene Therapy of Cancer. Academic Press, San Diego, CA, 1999, pp. 301-318.
26. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
27. Yang S, Darrow TL, Seigler HF: Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class 1-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Cancer Res 1997;57:1561-1568.
28. Schoenberger SP, Jonges LE, Mooijaart RJD, Hartgers F, Toes REM, Kast WM, et al.: Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res 1998;58:3094-3100.
29. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM: A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-1421.
30. Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG, et al.: Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 2001;61:228-236.
31. Chen L, Ashe S, Brady WA, et al.: Costimulation of antitumor immunity by the B7 counterreceptor for the T-lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102.
32. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-5807.
33. Zheng G, Chen A, Sterner RE, Zhang PJ, Pan T, Kiyatkin N, Tykocinski ML: Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res 2001;61:8127-8134.
34. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL: 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003-5010.
35. Stopeck AT, Hersh EM, Akporiaye ET, et al.: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341-349.
36. Boxhorn HKE, Smith JG, Chang YJ, et al.: Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunol Immunother 1998;46:283-292.
37. Braley-Mullen H, Tompson JG, Sharp GC, Kyriakos M: Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells. Cell Immunol 1980;51:408-413.
38. Billingham RE, Brent L, Medawar PB: Actively acquired tolerance to foreign cells. Nature 1953;172:603-606.
39. Wilson DB, Nowell PC: Quantitative studies on the mixed lymphocyte interaction in rats. Tempo and specificity of the proliferative response and the number of reactive cells from immunized donors. J Exp Med 1971;133:442-453.
40. Ildstad ST, Sachs DH: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-170.
41. Miller RG, Phillips RA: Reduction of the in vivo cytotoxic lymphocyte response produced by in vivo exposure to semiallogeneic cells: recruitment or active suppression? J Immunol 1976;117:1913-1921.
42. Rammensee H-G, Fink PJ, Bevan MJ: Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen. J Immunol 1984;133:2390-2396.
43. Miller RG: An immunological suppressor cell inactivating cytotoxic T lymphocyte precursor cells recognizing it. Nature 1980;287:544-546.
44. Fink PJ, Rammensee H-G, Bevan MJ: Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them. J Immunol 1984;133:1775-1781.
45. Hambor JE, Kaplan DR, Tykocinski ML: CD8 functions as an inhibitory ligand in mediating the immunoregulatory activity of CD8+ cells. J Immunol 1990;145:1646-1652.
46. Hambor JE, Weber MC, Tykocinski ML, Kaplan DR: Regulation of allogeneic responses by expression of CD8 alpha chain on stimulator cells. Int Immunol 1990;2:879-883.
47. Fayen J, Huang JH, Ferrone S, Tykocinski ML: Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. Int Immunol 1998;10:1347-1358.
48. Kaplan DR, Hambor JE, Tykocinski ML: An immunoregulatory function for the CD8 molecule. Proc Natl Acad Sci USA 1989;86:8512-8515.
49. Tykocinski ML, Kaplan DR: CD8-dependent immunoregulation: prospects for anti-rejection therapies based upon CD8 modification of alloantigen-presenting cells. Kidney Int 1993;43(Suppl 39):S120-S123.
50. Hambor JE, Tykocinski ML, Kaplan DR: Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone. J Exp Med 1988;168:1237-1245.
51. Sambhara SR, Miller RG: Programmed cell death of T cells signaled by the T cell receptor and the alpha3 domain of class I MHC. Science 1991;252:1424-1427.
52. Zhang L, Shannon J, Sheldon J, Teh HS, Mak TW, Miller RG: Role of infused CD8+ cells in the induction of peripheral tolerance. J Immunol 1994;152:2222-2228.
53. Qi Y, Berg R, Singleton MA, Debrick JE, Staerz UD: Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. J Exp Med 1996;183:1973-1980.
54. Sinclair NR: Why so many coinhibitory receptors? Scand J Immunol 1999;50:10-13.
55. Reich-Zeliger S, Zhao Y, Krauthgamer R, Bachar-Lustig E, Reisner Y: Anti-third party CD8+CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 2000;13:507-515.
56. Wu B, Wu, J-M, Miagkov A, Adams RN, Levitsky HI, Drachman DB: Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J Immunol 166:4773-4779.
57. Suss G, Shortman K: A subclass of dendritic cells kills CD4T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996;183:1789-1796.
58. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW: Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997;158:5676-5684.
59. George JF, Sweeney SD, Kirklin JK, Simpson EM, Goldstein DR, Thomas JM: An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med 1998;4:333-335.
60. Zhang H-G, Su X, Liu D, et al.: Induction of specifc T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999;162:1423-1430.
61. Giovarelli M, Musiani P, Garotta G, et al.: A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 1999;163:4886-4893.
62. Matsue H, Matsue K, Walters M, Okumura K, Yagita H, Takashima A: Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells. Nature Med 1999;5:930-937.
63. Min W-P, Gorczynski R, Huang X-Y, et al.: Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000;164:161-167.
64. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-480.
65. Turka LA, Linsley PS, Lin H, et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11,102-11,105.
66. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al.: Long term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
67. Wallace PM, Rodgers JN, Leytze GM, Johnson JS, Linsley PS: Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J Immunol 1995;154:5885-5895.
68. Shahinian A, Pfeffer K, Lee KP, et al.: Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609-611.
69. Huang J-H, Tykocinski ML: CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int Immunol 2001;13:529-539.
70. Mittrucker HW, Shahinian A, Bouchard D, Kundig TM, Mak TW: Induction of unresponsiveness and impaired T cell expansion by staphylococcal enterotoxin B in CD28-deficient mice. J Exp Med 1996;183:2481-2488.
71. Hoffmann P, Mueller N, Shively JE, Fleischer B, Neumaier M: Fusion proteins of B7.1 and a carcinoembryonic antigen (CEA)-specific antibody fragment opsonize CEA-expressing tumor cells and coactivate T-cell immunity. Int J Cancer 2001;92:725-732.
72. Rohrbach F, Gerstmayer B, Biburger M, Wels W: Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting. Clin Cancer Res 2000;6:4314-4322.
73. Schrama D, Straten P, Fischer WH, McLellan AD, Brocker E-B, Reisfeld RA, Becker JC: Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001;14:111-121.
74. Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC: Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 1996;56:1707-1712.
75. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML: Recombinant anti-human HER2/neuIgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumoractivity. J Immunol 2000;165:5112-5121.
76. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody-IL2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994;91:9626-9630.
77. Xu X, Clarke P, Szalai G, et al.: Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000;60:4475-4484.
78. van Broekhoven CL, Parish CR, Vassiliou G, Altin JG: Engrafting costimulator molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol 2000;164:2433-2443.